2022 Annual Meeting | C99 - Neurologic Complications of Novel Anti-neoplastic Therapies Including Immunotherapy
Program Materials Program Evaluations
01:00 PM - 01:05 PM PDT | Introduction |
Introduction to Course and Novel Cancer Therapies
Yazmin Odia, MD, MS, FAAN, FAAN |
01:00 PM - 01:00 PM PDT | Speaker |
Walk-in Slides
Yazmin Odia, MD, MS, FAAN, FAAN |
01:05 PM - 01:40 PM PDT | Speaker |
Complications of Cytotoxic, Biologic, and Hormone Therapies
Ekokobe Fonkem, DO |
01:40 PM - 02:15 PM PDT | Speaker |
Complications of Immunotherapies
Reena P. Thomas, MD, PhD, FAAN |
02:15 PM - 03:50 PM PDT | Speaker |
Complications of Radiation and Multimodal Therapies
Yazmin Odia, MD, MS, FAAN, FAAN |
03:50 PM - 04:00 PM PDT | Q&A |
Panel Discussion
Yazmin Odia, MD, MS, FAAN, FAAN, Reena P. Thomas, MD, PhD, FAAN, Ekokobe Fonkem, DO |
Yazmin Odia, MD, MS, FAAN, FAAN | Dr. Odia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile. |
Reena P. Thomas, MD, PhD, FAAN | The institution of Dr. Thomas has received research support from NIH. The institution of Dr. Thomas has received research support from California Institute of Regenerative Medicine. Dr. Thomas has received intellectual property interests from a discovery or technology relating to health care. |
Ekokobe Fonkem, DO | Dr. Fonkem has received personal compensation for serving as an employee of Barrow Neurological Institute. Dr. Fonkem has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Fonkem has stock in Global Cancer Technology. |